Currently Enrolling Research Studies

For more information, please click the appropriate Request More Information link in the studies outlined below OR simply call us at (919) 719-8826.


Alzheimer's Disease

TTP488-305 ELEVAGE


Title
: This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer’s disease and impaired glucose tolerance.

Purpose: The main purpose of this study is to learn how well azeliragon works and how safe the study drug is compared to placebo in participants with mild Alzheimer’s disease and high blood sugar.

Chance of Placebo: You will have a 1 in 2 chance of receiving study drug and a 1 in 2 chance you will be assigned to receive placebo.

Visit Schedule: You will be in this study for approximately 11 months, and you will have to come to the study center at least 5 times over this period along with the caregiver.


Key Inclusion Criteria

  • You should be age 50 to 85 years old
  • Have a clinical diagnosis of probable Alzheimer’s disease
  • At screening visit, a MMSE score ≥ 21-26
  • You should have a stable dosing regimen of symptomatic Alzheimer’s Disease treatment and oral treatment for diabetes

Key Exclusion Criteria

  • Current evidence or history of neurological or any other illness that could contribute to dementia
  • History of clinically significant or current unstable cardiac disease
  • Use of insulin therapy


Title
: A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study with an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects with Early Alzheimer’s Disease.

Purpose: To evaluate the efficacy of BAN2401 in subjects with early Alzheimer’s disease (EAD) by determining the superiority of BAN2401 compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment

Chance of Placebo: You have a 1 in 2 chance of receiving the study drug.

Visit Schedule: The visits occur on average once every 2 weeks and last between 2 and 6 hours.  Follow the 18 month placebo-controlled treatment period, there will be the option to enter an open-label extension study during which you are guaranteed to receive the active investigational product.


Key Inclusion Criteria

  • Be 50 to 90 years of age, inclusive
  • Have a diagnosis of Alzheimer’s Disease or Mild Cognitive Impairment
  • Have a MMSE score of ≥ 22
  • Identified study partner who is willing to participate for the study duration

Key Exclusion Criteria

  • Current evidence or history of neurological or any other illness that could contribute to dementia
  • History of clinically significant or current unstable cardiac disease
  • Use of insulin therapy

 

 

Headache/Migraine

3101-303-002 PROGRESS


Title
: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Chronic Migraine

Purpose: To evaluate the safety and tolerability of Atogepant 30mg BID and 60mg once a day for the prevention of chronic migraine

Chance of Placebo: You will have a 2 in 3 chance of receiving study drug and a 1 in 3 chance of receiving placebo.

Visit Schedule: The length of the study is 20 weeks from screening to follow-up.


Key Inclusion Criteria

  • Be between 18 to 80 years of age, inclusive, at Visit 2 with migraines that started before age 50.
  • At least a 1 year history of acute migraine with or without aura consistent with a diagnosis.
  • You have been diagnosed with chronic migraine (for example., have greater than or equal to 15 headache days per month) by your doctor.

Key Exclusion Criteria

  • You are not able to tell if your headache is a migraine headache or a tension type headache
  • You are taking a medication or will need to take medication that is not allowed in this study.  Your study doctor will discuss these medications with you.
  • You are a woman who is pregnant, nursing, or planning a pregnancy.

 

 

Multiple Sclerosis There are currently no MS studies enrolling at this time. Please check back soon!

 

 

Pain There are currently no Pain studies enrolling at this time. Please check back soon!

 

 

Parkinson's Disease

NLY01-PD-1 NEURALY


Title
: A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 36 weeks treatment with NLY01 in Early-Stage Parkinson’s Disease (PD)

Purpose: Researchers want to know whether NLY01 helps lessen symptoms and signs of early Parkinson’s disease and whether it slows the progression of Parkinson’s disease

Chance of Placebo: You will have a 2 in 3 chance of receiving NLY01 and a 1 in 3 chance of receiving placebo.

Visit Schedule: The total study duration will be about one year.


Key Inclusion Criteria

  • Age 30-80
  • Diagnosis of Parkinson’s Disease

Key Exclusion Criteria

  • Significant memory loss, active major depression, or significant renal impairment
  • Previous surgical procedure for Parkinson’s Disease, like Deep Brain Stimulation
  • Current treatment with levodopa, pramipexole, ropinirole, neupro, azilect, amantadine, and/or entacapone
  • Use of marijuana within the last 3 months
  • Current participation in another investigational clinical trial

PL101-LID201 GLIDE


Title
: A Double-Blind, Randomized, Three-Arm, Parallel-Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine versus Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease (gLIDe)

Purpose: The purpose of this study, which involves research, is to determine if an investigational drug, pridopidine, is safe and effective in the treatment of PD-LID. PD-LID are frequently writhing, twisting involuntary movements that may interfere with daily activity.

Chance of Placebo: You will have a 2 in 3 chance of receiving the Pridopidine, and a 1 in 3 of receiving placebo.

Visit Schedule: If you decide to participate in this study, you will be asked to make a total of 8 visits to the study site over the next 21-27 weeks; each visit will take approximately 3-5 hours.


Key Inclusion Criteria

  • Be between 30 to 85 years of age
  • Have a clinical diagnosis of Parkinson’s Disease
  • Have clinical documentation of mild-to-severe LID by the research doctor

Key Exclusion Criteria

  • Have a diagnosis of atypical parkinsonism
  • Having treatment with dopamine blocking drugs
  • Having a history of surgical intervention related to PD (e.g. deep brain stimulation, carbidopa-levodopa enteral suspension [CLES, DuopaTM])
  • History of certain cancers within five years of screening

 

 

Pediatric Neurology

800MS301 BLAST


Title
: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis

Purpose: The aim of this study is to check if and how well two study drugs (BG00012 and BIIB017) work in children who have a type of multiple sclerosis (MS) called relapsing-remitting multiple sclerosis (RRMS)

Chance of Placebo: 1:2:2 ratio with a 40% chance of receiving placebo

Visit Schedule: Study duration totals 96 weeks including 10-12 onsite visits and 7 phone visits.


Key Inclusion Criteria

  • Be 10 to 17 years of age
  • Must have a diagnosis of Relapsing-remitting multiple sclerosis
  • You have had at least 1 relapse in the past 12 months

Key Exclusion Criteria

  • Previous treatment with Fumaderm, Tecfidera, or Plegridy
  • There are several exclusionary medications/DMTs that the study coordinator can provide upon request.

 

 

Seizures/Epilepsy There are currently no Seizure/Epilepsy studies enrolling at this time. Please check back soon!

 

 

Sleep Medicine There are currently no Sleep Medicine studies enrolling at this time. Please check back soon!

 

 

Stroke There are currently no Stroke studies enrolling at this time. Please check back soon!

 

 

Other Neurological Indications There are currently no other studies enrolling at this time. Please check back soon!